KCPG
VRDN icon

Kavar Capital Partners Group’s Viridian Therapeutics VRDN Stock Holding History

Kavar Capital Partners Group’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-40
Closed -$4K – 373
2018
Q2 		$4K Hold
40
– – ﹤0.01% 384
2018
Q1 		$4K Buy
+40
New +$4.35K ﹤0.01% 380

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BWP
BSW Wealth Partners Boulder, Colorado $899M AUM 28.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Kavar Capital Partners Group's VRDN Position: Q3 2018 in Review

Kavar Capital Partners Group sold out of Viridian Therapeutics (VRDN) in Q3 2018, closing a stake of 40 shares — an estimated $4K sold.

Kavar Capital Partners Group first reported a position in VRDN in Q1 2018 and held it in 2 quarters. The position peaked at $4K in Q2 2018. 57 funds tracked by Wall St. Rank hold VRDN as of Q3 2018.

  • Kavar Capital Partners Group reported no remaining Viridian Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Kavar Capital Partners Group sold 40 Viridian Therapeutics shares in Q3 2018, an estimated $4K.
  • Kavar Capital Partners Group first reported a position in Viridian Therapeutics in Q1 2018 and held it in 2 quarters.
  • Kavar Capital Partners Group's Viridian Therapeutics position peaked at $4K in Q2 2018.
  • 57 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2018.

Based on Kavar Capital Partners Group's 13F filing for Q3 2018, filed 9 Nov 2018.